New York-Presbyterian/Columbia University Irving Medical Center - Herbert Irving Comprehensive Cancer Center (HICCC) is a clinical research site located in New York, New York, United States 10032.
Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.
New York-Presbyterian/Columbia University Irving Medical Center - Herbert Irving Comprehensive Cancer Center (HICCC) has participated in 1 clinical trials with 1 currently active.
Therapeutic areas: Relapsed or Refractory T Cell Lymphoma.
Sponsors: Ono Pharmaceutical Co. Ltd.
Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
New York-Presbyterian/Columbia University Irving Medical Center - Herbert Irving Comprehensive Cancer Center (HICCC) has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
New York-Presbyterian/Columbia University Irving Medical Center - Herbert Irving Comprehensive Cancer Center (HICCC) has 1 clinical trials on record, with 1 currently active. Their work covers Relapsed or Refractory T Cell Lymphoma.
New York-Presbyterian/Columbia University Irving Medical Center - Herbert Irving Comprehensive Cancer Center (HICCC) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.